Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of PF-06823859 in Active Idiopathic Inflammatory Myopathies (Dermatomyositis and Polymyositis)
CTR20232664Phase 3Active
- Sponsor
- Pfizer
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dazukibart in dermatomyositis (DM), Autoimmune Myopathies, sponsored by Pfizer. Started Jan 2024; status: active.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)Autoimmune Myopathies
Beyond the preview
Go deeper on CTR20232664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232664.